Two UK firms announce plans to begin trials of therapies to tackle Coronavirus, PrEP is to be available for patients in England from April, the risk of death by stroke is down 24%, and Merck / MSD’s chronic cough drug clears phase 3 trials, potentially setting up regulatory filings this year.
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Operations Director, Mark Ward, on 07872 105 540 or email email@example.com.
On the hunt for a new role, or just curious?
The US biotech Moderna was just about the only stock on the rise yesterday amid the global COVID-19 bear market, as the Massachusetts firm announced the first patient had been tested with its potential coronavirus vaccine.
Two UK firms have announced plans to begin trials of therapies to tackle the coronavirus outbreak.
From April, the Department of Health and Social Care will ensure that everyone at high risk of contracting HIV will receive PrEP from their local sexual health clinic.
The National Institute for Health Research (NIHR) has revealed that the risk of death and disability after a stroke fell significantly between 2000 and 2015.
Merck & Co/MSD’s experimental drug gefapixant has improved the frequency of coughing in a pair of phase 3 trials, potentially setting up regulatory filings this year.
While you’re here…
…and are interested in our content, why not sign up to our newsletter?
It’s just below.